KRAS and neoplasm: T-cell receptor (TCR)–based therapy uses genetically engineered lymphocytes to target antigens derived from tumor-specific proteins [e.g., cancer testis antigens (CTA) and mutated tumor antigens, such as KRAS] presented by HLA molecules on the tumor cell surface as “non-self neoantigens” and can generate a T-cell immune response (17).